GlassScriptPhysician profile
Jeffrey P Ross
NPI 1033179841
$5,290.16
in general payments reported to CMS, 2019-2025
18 companies · $1,078 in 2025
The $1,078 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $685 · 2020: $216 · 2021: $443 · 2022: $918 · 2023: $873 · 2024: $1,077 · 2025: $1,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,931 · Education: $96.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,930.77 |
| Education | $96.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,300.27 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $1,055.36 | 2019-2025 | Biktarvy |
| Abbvie INC. | $915.42 | 2019-2025 | Dalvance, Mavyret, Teflaro |
| Merck Sharp & Dohme LLC | $841.90 | 2019-2025 | Pifeltro, Dificid, Delstrigo |
| Astellas Pharma US INC | $539.65 | 2019-2024 | Cresemba |
| Ferring Pharmaceuticals INC. | $101.55 | 2022-2023 | Rebyota |
| Insmed, INC. | $87.92 | 2019-2025 | Arikayce |
| Pfizer INC. | $75.82 | 2024-2025 | |
| Glaxosmithkline, LLC. | $73.99 | 2019-2024 | Shingrix, Arexvy |
| La Jolla Pharmaceutical Company | $63.76 | 2022-2025 | Zevtera |
| Aimmune Therapeutics, INC. | $56.73 | 2025 | Zenpep |
| Cumberland Pharmaceuticals, INC. | $42.70 | 2024-2025 | Vibativ |
| Janssen Biotech, INC. | $36.98 | 2021 | |
| Paratek Pharmaceuticals, INC. | $33.61 | 2024-2025 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.29 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $19.28 | 2022 | |
| Allergan, INC. | $12.82 | 2020 | |
| Dynavax Technologies Corporation | $12.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.